Attached files
file | filename |
---|---|
EX-99.2 - PRESS RELEASE - CATALYST BIOSCIENCES, INC. | dex992.htm |
EX-99.1 - SLIDE PRESENTATION - CATALYST BIOSCIENCES, INC. | dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 15, 2009
TARGACEPT, INC.
(Exact name of registrant as specified in its charter)
Delaware | 000-51173 | 56-2020050 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
200 East First Street, Suite 300 Winston-Salem, North Carolina |
27101 | |
(Address of principal executive offices) | (Zip Code) |
(336) 4802100
Registrants telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. | Other Events. |
On October 15, 2009, Geoffrey C. Dunbar, M.D., Vice President, Clinical Development and Regulatory Affairs of Targacept, Inc. (Targacept), presented data from Targacepts completed Phase 2b clinical trial of TC-5214 as an augmentation treatment for major depressive disorder at the Nicotinic Acetylcholine Receptors as Therapeutic Targets Symposium (the Symposium), a satellite meeting of the 39th annual meeting of the Society for Neuroscience. The slide presentation made at the Symposium by Dr. Dunbar is attached to this Current Report on Form 8-K as Exhibit 99.1. A related press release issued by Targacept is attached to this Current Report on Form 8-K as Exhibit 99.2.
Item 9.01. | Financial Statements and Exhibits. |
(d) | Exhibits |
The following exhibits are filed with this report:
Exhibit Number |
Description | |
99.1 | Slide presentation made at the Nicotinic Acetylcholine Receptors as Therapeutic Targets Symposium on October 15, 2009 | |
99.2 | Press release dated October 15, 2009 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TARGACEPT, INC. | ||||
Date: October 15, 2009 | /S/ PETER A. ZORN | |||
Peter A. Zorn | ||||
Vice President, Legal Affairs and General Counsel |
EXHIBIT INDEX
Exhibit Number |
Description | |
99.1 | Slide presentation made at the Nicotinic Acetylcholine Receptors as Therapeutic Targets Symposium on October 15, 2009 | |
99.2 | Press release dated October 15, 2009 |